Protagonist Therapeutics Inc
PTGX85.400USD
+1.200+1.43%
收盤 11/21, 16:00（美東）報價延遲15分鐘
5.29B總市值
10.01本益比TTM
關於 Protagonist Therapeutics Inc 公司
Protagonist Therapeutics, Inc. 是一家生物製藥公司。該公司使用其肽基化學實體 rusfertide 和 JNJ-2113 進行不同的開發，這些實體均源自其專有的發現技術平臺。該公司的臨牀項目分爲兩類疾病：血液學和血液疾病以及炎症和免疫調節疾病。其主要臨牀資產 rusfertide (PTG-300) 是一種可注射的鐵調素類似物，正在開發中，用於治療真性紅細胞增多症 (PV) 和其他血液疾病。該公司的白細胞介素-23 受體 (IL-23R) 拮抗劑化合物 JNJ-2113 是一種口服的試驗藥物，旨在阻斷已上市的可注射抗體藥物所針對的生物途徑。其 PN-943 是一種全資研究的口服腸道限制性 α4β7（α4β7）特異性整合素拮抗劑，用於治療炎症性腸病（IBD）。
Protagonist Therapeutics Inc簡介
公司代碼PTGX
公司名稱Protagonist Therapeutics Inc
上市日期Aug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
員工數量126
證券類型Ordinary Share
年結日Aug 11
公司地址7707 Gateway Blvd Ste 140
城市NEWARK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94560-1160
電話15104740170
網址https://www.protagonist-inc.com/
公司代碼PTGX
上市日期Aug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Protagonist Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
名稱
名稱/職務
職務
持股
持股變動
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月19日 週三
更新時間: 11月19日 週三
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
股東類型
持股股東
佔比
Investment Advisor
38.79%
Investment Advisor/Hedge Fund
35.88%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.46M
13.6%
-140.21K
-1.63%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.17M
9.92%
+65.00K
+1.06%
Jun 30, 2025
RTW Investments L.P.
5.76M
9.25%
+36.86K
+0.64%
Jun 30, 2025
The Vanguard Group, Inc.
4.35M
6.99%
+80.38K
+1.88%
Jun 30, 2025
State Street Investment Management (US)
3.21M
5.16%
+500.92K
+18.51%
Jun 30, 2025
BVF Partners L.P.
3.21M
5.16%
+636.03K
+24.70%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.94%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.04M
1.67%
+50.37K
+5.10%
Jun 30, 2025
UBS Financial Services, Inc.
2.50M
4.02%
+2.15M
+619.02%
Jun 30, 2025
Deep Track Capital LP
3.25M
5.22%
-4.10K
-0.13%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco S&P SmallCap Health Care ETF
2.47%
ALPS Medical Breakthroughs ETF
2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
2.13%
ETC 6 Meridian Small Cap Equity ETF
1.29%
SPDR S&P Biotech ETF
1.28%
Cambria Value and Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Invesco S&P SmallCap Momentum ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.67%
查看更多
Invesco S&P SmallCap Health Care ETF
佔比2.47%
ALPS Medical Breakthroughs ETF
佔比2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比2.13%
ETC 6 Meridian Small Cap Equity ETF
佔比1.29%
SPDR S&P Biotech ETF
佔比1.28%
Cambria Value and Momentum ETF
佔比1%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.85%
Invesco S&P SmallCap Momentum ETF
佔比0.77%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.67%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Protagonist Therapeutics Inc的前五大股東是誰？
Protagonist Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.持有股份：8.46M佔總股份比例：13.60%。
Farallon Capital Management, L.L.C.持有股份：6.17M佔總股份比例：9.92%。
RTW Investments L.P.持有股份：5.76M佔總股份比例：9.25%。
The Vanguard Group, Inc.持有股份：4.35M佔總股份比例：6.99%。
State Street Investment Management (US)持有股份：3.21M佔總股份比例：5.16%。
BlackRock Institutional Trust Company, N.A.持有股份：8.46M佔總股份比例：13.60%。
Farallon Capital Management, L.L.C.持有股份：6.17M佔總股份比例：9.92%。
RTW Investments L.P.持有股份：5.76M佔總股份比例：9.25%。
The Vanguard Group, Inc.持有股份：4.35M佔總股份比例：6.99%。
State Street Investment Management (US)持有股份：3.21M佔總股份比例：5.16%。
Protagonist Therapeutics Inc的前三大股東類型是什麼？
Protagonist Therapeutics Inc 的前三大股東類型分別是：
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
有多少機構持有Protagonist Therapeutics Inc(PTGX)的股份？
截至2025Q3，共有551家機構持有Protagonist Therapeutics Inc的股份，合計持有的股份價值約為71.95M，占公司總股份的115.09% 。與2025Q2相比，機構持股有所增加，增幅為5.78%。
哪個業務部門對Protagonist Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Protagonist Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
